Our Story
SL BIO Ltd. (SL BIO) is focused on developing groundbreaking cellular and gene therapies while expanding its established portfolio of regenerative medicine and cancer treatment. Our research concentrates on investigational immune cell technologies currently in pre-clinical development, including proprietary Armed-T and Gamma delta T cells, as well as novel exosome portfolio formulated from non-human resources such as plant and bovine milk. These parallel efforts position SL BIO at the intersection of translational immunology and early-stage regenerative science. In 2024, SL BIO completed a strategic capital raise and investment framework restructuring to support long-term growth across both immune-based R&D programs and non-therapeutic formulation platforms.
Our Vision & Commitment
SL BIO’s vision is to contribute to the future of healthcare by advancing research-driven innovation in immune cell science and non-cellular biologics. Our work is focused on supporting the development of preclinical platforms both cell-based and cell-free that are designed for investigational use across oncology and regenerative research applications.
We are committed to ethical research, scientific transparency, and responsible innovation. Our development efforts include immune cell redirection platforms and exosome-based formulation systems sourced from plant and milk-derived materials, with applications in both cancer research and topical formulation science.
Through sustained investment in early-stage R&D and collaborative partnerships, SL BIO aims to deliver high-integrity innovation that aligns with long-term goals in translational research and global scientific advancement.
